250 related articles for article (PubMed ID: 17697391)
1. BCoR-L1 variation and breast cancer.
Lose F; Arnold J; Young DB; Brown CJ; Mann GJ; Pupo GM; ; Khanna KK; Chenevix-Trench G; Spurdle AB
Breast Cancer Res; 2007; 9(4):R54. PubMed ID: 17697391
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the BRCA1-interacting genes ZNF350/ZBRK1 and BRIP1/BACH1 among BRCA1 and BRCA2-negative probands from breast-ovarian cancer families and among early-onset breast cancer cases and reference individuals.
Rutter JL; Smith AM; Dávila MR; Sigurdson AJ; Giusti RM; Pineda MA; Doody MM; Tucker MA; Greene MH; Zhang J; Struewing JP
Hum Mutat; 2003 Aug; 22(2):121-8. PubMed ID: 12872252
[TBL] [Abstract][Full Text] [Related]
3. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
4. BRCA1 and BRCA2 have a limited role in familial prostate cancer.
Sinclair CS; Berry R; Schaid D; Thibodeau SN; Couch FJ
Cancer Res; 2000 Mar; 60(5):1371-5. PubMed ID: 10728701
[TBL] [Abstract][Full Text] [Related]
5. High incidence of skewed X chromosome inactivation in young patients with familial non-BRCA1/BRCA2 breast cancer.
Kristiansen M; Knudsen GP; Maguire P; Margolin S; Pedersen J; Lindblom A; Ørstavik KH
J Med Genet; 2005 Nov; 42(11):877-80. PubMed ID: 15879497
[TBL] [Abstract][Full Text] [Related]
6. Variation in the RAD51 gene and familial breast cancer.
Lose F; Lovelock P; Chenevix-Trench G; Mann GJ; Pupo GM; Spurdle AB;
Breast Cancer Res; 2006; 8(3):R26. PubMed ID: 16762046
[TBL] [Abstract][Full Text] [Related]
7. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
[TBL] [Abstract][Full Text] [Related]
8. CGH analysis of familial non-BRCA1/BRCA2 breast tumors and mutation screening of a candidate locus on chromosome 17q11.2-12.
Maguire P; Holmberg K; Kost-Alimova M; Imreh S; Skoog L; Lindblom A
Int J Mol Med; 2005 Jul; 16(1):135-41. PubMed ID: 15942690
[TBL] [Abstract][Full Text] [Related]
9. Mutation analysis and characterization of ATR sequence variants in breast cancer cases from high-risk French Canadian breast/ovarian cancer families.
Durocher F; Labrie Y; Soucy P; Sinilnikova O; Labuda D; Bessette P; Chiquette J; Laframboise R; Lépine J; Lespérance B; Ouellette G; Pichette R; Plante M; Tavtigian SV; Simard J
BMC Cancer; 2006 Sep; 6():230. PubMed ID: 17010193
[TBL] [Abstract][Full Text] [Related]
10. Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes.
Machado PM; Brandão RD; Cavaco BM; Eugénio J; Bento S; Nave M; Rodrigues P; Fernandes A; Vaz F
J Clin Oncol; 2007 May; 25(15):2027-34. PubMed ID: 17513806
[TBL] [Abstract][Full Text] [Related]
11. A high proportion of DNA variants of BRCA1 and BRCA2 is associated with aberrant splicing in breast/ovarian cancer patients.
Sanz DJ; Acedo A; Infante M; Durán M; Pérez-Cabornero L; Esteban-Cardeñosa E; Lastra E; Pagani F; Miner C; Velasco EA
Clin Cancer Res; 2010 Mar; 16(6):1957-67. PubMed ID: 20215541
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
13. Regulation of BRCA1 and BRCA2 expression in human breast cancer cells by DNA-damaging agents.
Andres JL; Fan S; Turkel GJ; Wang JA; Twu NF; Yuan RQ; Lamszus K; Goldberg ID; Rosen EM
Oncogene; 1998 Apr; 16(17):2229-41. PubMed ID: 9619832
[TBL] [Abstract][Full Text] [Related]
14. Use of expression data and the CGEMS genome-wide breast cancer association study to identify genes that may modify risk in BRCA1/2 mutation carriers.
Walker LC; Waddell N; Ten Haaf A; ; Grimmond S; Spurdle AB
Breast Cancer Res Treat; 2008 Nov; 112(2):229-36. PubMed ID: 18095154
[TBL] [Abstract][Full Text] [Related]
15. BRCA1 and BRCA2: the genetic testing and the current management options for mutation carriers.
Palma M; Ristori E; Ricevuto E; Giannini G; Gulino A
Crit Rev Oncol Hematol; 2006 Jan; 57(1):1-23. PubMed ID: 16337408
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer susceptibility testing: past, present and future.
Goldberg JI; Borgen PI
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1205-14. PubMed ID: 16925486
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of the ATR gene in breast and ovarian cancer families.
Heikkinen K; Mansikka V; Karppinen SM; Rapakko K; Winqvist R
Breast Cancer Res; 2005; 7(4):R495-501. PubMed ID: 15987455
[TBL] [Abstract][Full Text] [Related]
18. Twenty-three novel BRCA1 and BRCA2 sequence alterations in breast and/or ovarian cancer families of Eastern Spain.
Esteban Cardeñosa E; Bolufer Gilabert P; Palanca Suela S; Oltra Soler S; Barragán González E; Velasco Sampedro E; Chirivella González I; Segura Huerta A; Guillén Ponce C; Martínez de Dueñas E;
Breast Cancer Res Treat; 2008 Nov; 112(1):69-73. PubMed ID: 18060494
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of the PALB2 susceptibility gene in inherited and sporadic breast and ovarian cancer.
Potapova A; Hoffman AM; Godwin AK; Al-Saleem T; Cairns P
Cancer Res; 2008 Feb; 68(4):998-1002. PubMed ID: 18281473
[TBL] [Abstract][Full Text] [Related]
20. Analysis of FANCB and FANCN/PALB2 fanconi anemia genes in BRCA1/2-negative Spanish breast cancer families.
García MJ; Fernández V; Osorio A; Barroso A; Llort G; Lázaro C; Blanco I; Caldés T; de la Hoya M; Ramón Y Cajal T; Alonso C; Tejada MI; San Román C; Robles-Díaz L; Urioste M; Benítez J
Breast Cancer Res Treat; 2009 Feb; 113(3):545-51. PubMed ID: 18302019
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]